NRx Pharmaceuticals, Inc. (NRXPW) Análise de ações

Visão geral da empresa

A clinical-stage bio-pharmaceutical enterprise, NRx Pharmaceuticals, Inc., focuses on the development of novel therapeutics designed to address central nervous system disorders, specifically targeting conditions such as suicidal depression, post-traumatic stress disorder, and chronic pain. The company operates within the N/A sector and the N/A industry, classifications that reflect its specialized positioning in a niche therapeutic area rather than a broad market classification. NRx Pharmaceuticals, Inc. maintains a scale defined by an annual revenue of $1.23 million and employs a workforce of 29 individuals to execute its research and development initiatives. The valuation metrics present a complex picture of the company's position, as the market cap is listed as N/A, which typically indicates that the security trades over-the-counter or lacks sufficient liquidity to derive a standard market capitalization, while the revenue figure suggests the business is in an early commercialization or pre-commercialization phase where revenue generation is currently limited.

Saúde financeira

The financial statements for the trailing twelve months reveal a revenue of $1.23 million, a net income of $-28,622,000, and an EBITDA of $-16,118,000, highlighting a significant disparity between top-line sales and bottom-line profitability. The gap between the $1.23 million in revenue and the substantial net loss indicates a cost structure heavily weighted toward research and development expenses or operational overheads that have not yet been offset by gross margins. Free cash flow stands at $-805,875, a figure that signals the company is consuming cash reserves rather than generating liquidity, thereby limiting its immediate financial flexibility to fund operations without external capital raises. The company holds $7.80 million in cash against $631,000 in debt, creating a substantial liquidity buffer that allows the firm to continue operations despite ongoing cash burn. Analysis of the three primary margins shows a gross margin of 58.8%, an operating margin of -467.3%, and a profit margin of 0.0%, illustrating that while the product mix is reasonably priced relative to the cost of goods sold, operating expenses are disproportionately high compared to sales. The operating margin of -467.3% is mathematically indicative of expenses significantly exceeding revenue, a common characteristic in clinical-stage biopharmaceuticals before product launch. Return on Equity is listed as N/A, while the Return on Assets is recorded at -121.8%, metrics that collectively reveal that management is utilizing the company's asset base to generate losses rather than returns at this stage. Regarding short-term liquidity, the current ratio is 0.31, which indicates that current assets are less than one-third of current liabilities, suggesting a potential liquidity constraint where the company may struggle to meet obligations without relying on its cash hoard or additional financing.

Avaliação de valorização

The valuation metrics for NRx Pharmaceuticals, Inc. show a P/E Ratio (TTM) and Forward P/E both listed as N/A, reflecting the reality that traditional earnings-based valuation multiples are inapplicable due to the company's persistent net losses. The price-to-book ratio is stated as -0.03, a negative figure that technically indicates the market capitalization is below the book value of equity, often seen in distressed situations or, in this case, where the accounting book value exceeds the market price due to the N/A market cap status. The price-to-sales ratio is N/A, and the EV/EBITDA is also N/A, suggesting that investors cannot rely on these standard multiples to gauge value and must instead look at cash burn rates and asset liquidity. The 52-week high and low for the stock are both recorded at $0.02, meaning the current trading price is effectively at the bottom of its observed range, or trading at 0% below the 52-week high given the lack of price appreciation over the past year. The beta value is 1.83, which indicates that the stock's price volatility is significantly higher than the broader market, moving with 1.83 times the intensity of the overall market index.

Growth & Income

Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, which implies that there is no historical comparative data available to calculate a growth rate, likely due to the company's recent inception or lack of audited financial reporting in previous periods. Since the company is not a dividend payer, the dividend yield and payout ratio are both N/A, confirming that NRx Pharmaceuticals, Inc. does not distribute any portion of its earnings to shareholders. Instead of paying dividends, the company retains its earnings, which are currently negative, to reinvest into its drug candidates like NRX-101 and its ongoing clinical development programs. The overall growth and income profile is characterized by a complete absence of current earnings growth or dividend income, with the company's primary value proposition resting entirely on the potential future success of its pipeline rather than current financial performance or shareholder distributions.